隐源性卒中后QTc延长:信号、替代指标还是混杂因素?
本文围绕ARCADIA试验中881例隐源性卒中合并心房心脏病患者展开,这些患者被随机分配接受阿司匹林或阿哌沙班治疗。既往观点认为QTc延长提示不良心血管风险,但该试验显示QTc延长与较低的复发性卒中风险相关。作者认为这一发现与直觉相悖,需谨慎解读其临床意义。
要点
- QTc延长传统上被视为心律失常和死亡风险升高的标志。
- ARCADIA试验中QTc延长与隐源性卒中患者复发性卒中风险较低相关。
- 该关联方向与既往认知相反,临床解读需谨慎。
核心结论
- 在ARCADIA试验的881例隐源性卒中合并心房心脏病患者中,QTc延长与较低的复发性卒中风险相关。
- 该发现与传统认为QTc延长提示不良心血管风险的观点相反,作者认为其临床意义难以直接解释。
研究设计与样本
- 研究对象来自ARCADIA试验,共纳入881例隐源性卒中和心房心脏病患者。
- ARCADIA为双盲、安慰剂对照试验,患者被随机分配接受阿司匹林或阿哌沙班治疗。
- 阿哌沙班用法为5 mg每日两次,符合标准减量条件时减至2.5 mg每日两次。
主要发现
- 既往人群研究显示,无卒中史的QTc延长个体发生缺血性卒中的风险较高。
- ARCADIA试验中QTc延长与复发性卒中风险较低相关,该方向与传统认知相反。
关键数值与推荐
- 阿哌沙班剂量为5 mg每日两次,符合标准减量条件时减至2.5 mg每日两次。
局限性
- 作者认为QTc延长与复发性卒中风险较低的关联与直觉相悖,其机制和临床解释尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The corrected QT interval (QTc) has traditionally been regarded as a marker of adverse cardiovascular biology. 1 2 Prolonged ventricular repolarisation has been associated with arrhythmic risk, autonomic dysfunction and excess mortality, and population-based studies have reported a higher risk of incident ischaemic stroke among individuals with prolonged QTc and no prior history of stroke. 1 2 Against this background, Boursiquot and colleagues report in the accompanying manuscript that QTc prolongation was associated with a lower risk of recurrent stroke among 881 participants from the Atrial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA) trial, a double-blind, placebo-controlled trial that randomised patients with cryptogenic stroke (CS) and atrial cardiopathy to aspirin or apixaban. 5 mg two times per day (with dose reduction to 2.5 mg two times per day when standard criteria were met). 3 This finding appears counterintuitive and difficult to...
引用
- Heart:QTc prolongation after cryptogenic stroke: signal, surrogate or confounder?
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。